ER-Positive Metastatic Breast Cancer — An Interview with Prof Patrick Neven on the Role of Oral Selective Estrogen Receptor Degraders (Companion Faculty Lecture)

<p class="MsoNormal">Featuring a slide presentation and related discussion from Prof Patrick Neven, including the following topics:</p> <ul> <li>Biology of the estrogen receptor (ER) and mechanisms of resistance to therapy (0:00)</li> <li>Clinical trial data involving oral selective ER degraders (SERDs) for endocrine-resistant ER-positive, HER2-negative metastatic breast cancer (13:34)</li> <li>Utility of switching to an oral SERD before radiographic disease progression for patients receiving first-line endocrine treatment (23:12)</li> <li>Ongoing trials with oral SERDs for ER-positive, HER2-negative breast cancer (27:13)</li> <li>Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant upon disease progression on first-line letrozole (32:34)</li> <li>Case: Patient with ER-positive, HER2-negative breast cancer receives imlunestrant/abemaciclib upon relapse on letrozole/abemaciclib (34:16)</li> <li>Case: Patient with ER-positive, HER2-negative breast cancer rece...